Unichem Laboratories Ltd

Unichem Labs. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Unichem Laboratories Ltd

₹ 606 -3.87%
13 Jun - close price
unichemlabs.com BSE: 506690 NSE: UNICHEMLAB
About

Unichem Laboratories Ltd is involved in pharmaceuticals
in Generics, APIs and Contract Manufacturing (CMO) areas.[1]

Key Points

Therapeutic Areas
The company manufactures and markets APIs and pharmaceutical formulations as branded & non-branded generics. The company’s products cater to diverse therapeutic areas such as cardiology, gas, diabetology, gastroenterology psychiatry, neurology, antibacterial, anti-infective, and pain management. [1]

Website BSE NSE
  • Market Cap ₹ 4,267 Cr.
  • Current Price ₹ 606
  • High / Low ₹ 950 / 510
  • Stock P/E 26.8
  • Book Value ₹ 349
  • Dividend Yield 0.00 %
  • ROCE 7.53 %
  • ROE 6.70 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has delivered good profit growth of 37.4% CAGR over last 5 years

Cons

  • Company has a low return on equity of -1.01% over last 3 years.
  • Company has high debtors of 157 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE SmallCap BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
277 245 266 252 310 347 334 362 399 390 437 448 461
264 256 297 294 319 338 341 343 369 350 372 374 386
Operating Profit 12 -11 -31 -42 -9 8 -7 19 31 40 64 74 75
OPM % 5% -4% -12% -17% -3% 2% -2% 5% 8% 10% 15% 17% 16%
9 12 6 15 -104 6 8 78 -119 9 7 19 10
Interest 1 2 3 2 3 2 4 2 2 1 2 3 2
Depreciation 21 23 26 29 28 27 27 26 25 26 26 28 27
Profit before tax -0 -23 -55 -57 -144 -16 -31 69 -115 21 43 62 56
Tax % -6,289% 0% 38% 0% 0% 0% 0% 0% 0% 0% 0% 24% 9%
17 -23 -75 -57 -144 -16 -31 69 -115 21 43 47 51
EPS in Rs 2.46 -3.31 -10.72 -8.11 -20.43 -2.23 -4.38 9.84 -16.33 3.05 6.16 6.66 7.27
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
1,044 1,091 1,221 576 666 968 904 1,124 943 1,072 1,442 1,736
863 989 1,078 813 798 1,019 994 1,028 986 1,165 1,391 1,482
Operating Profit 181 102 142 -237 -132 -52 -89 95 -43 -93 51 254
OPM % 17% 9% 12% -41% -20% -5% -10% 8% -5% -9% 4% 15%
84 20 19 366 2,737 94 98 47 42 -71 -27 45
Interest 2 2 2 2 3 1 1 1 2 9 10 8
Depreciation 43 38 35 39 45 62 71 76 83 106 105 108
Profit before tax 220 82 124 87 2,556 -20 -64 66 -87 -279 -92 183
Tax % 20% 21% 19% -19% -0% -144% -12% 18% -36% 7% 0% 11%
177 64 100 104 2,557 9 -56 54 -55 -300 -92 163
EPS in Rs 19.52 7.09 11.06 11.43 363.48 1.25 -8.00 7.68 -7.87 -42.57 -13.09 23.15
Dividend Payout % 41% 28% 18% 26% 1% 320% -50% 52% -51% -9% 0% 0%
Compounded Sales Growth
10 Years: 5%
5 Years: 14%
3 Years: 23%
TTM: 20%
Compounded Profit Growth
10 Years: 10%
5 Years: 37%
3 Years: 70%
TTM: 540%
Stock Price CAGR
10 Years: 12%
5 Years: 30%
3 Years: 35%
1 Year: 10%
Return on Equity
10 Years: 11%
5 Years: -1%
3 Years: -1%
Last Year: 7%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 18 18 18 18 14 14 14 14 14 14 14 14
Reserves 888 929 1,009 1,113 2,748 2,718 2,633 2,683 2,658 2,370 2,281 2,446
1 0 8 1 0 0 17 1 132 108 70 123
300 274 306 371 346 298 361 420 318 394 499 527
Total Liabilities 1,207 1,222 1,342 1,503 3,108 3,030 3,025 3,119 3,122 2,886 2,864 3,109
394 396 381 468 555 789 829 850 963 1,236 1,165 1,275
CWIP 86 119 233 247 236 90 331 568 494 148 122 31
Investments 120 153 111 89 979 1,042 668 520 390 41 44 46
607 555 617 698 1,338 1,109 1,197 1,181 1,275 1,462 1,532 1,758
Total Assets 1,207 1,222 1,342 1,503 3,108 3,030 3,025 3,119 3,122 2,886 2,864 3,109

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
87 88 117 141 -66 -251 -42 -33 -158 -117 -42 72
35 -62 -87 -132 1,648 -323 -36 -73 104 241 60 -132
-98 -47 -39 -9 -930 -45 -21 -45 96 -62 -48 -5
Net Cash Flow 24 -21 -9 -0 653 -619 -98 -150 42 62 -30 -64

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 74 69 79 188 127 125 130 117 147 161 141 157
Inventory Days 183 159 162 371 216 242 301 326 438 335 264 267
Days Payable 149 122 153 334 220 170 199 159 150 170 132 120
Cash Conversion Cycle 108 106 88 225 123 197 233 284 436 325 274 305
Working Capital Days 102 95 100 233 190 222 221 208 286 267 206 212
ROCE % 19% 9% 13% -8% 132% -0% -2% 2% -3% -6% -1% 8%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
50.93% 50.94% 50.94% 50.94% 50.94% 70.21% 70.22% 70.22% 70.22% 70.22% 70.22% 70.22%
1.50% 1.71% 1.56% 1.70% 1.62% 0.83% 0.84% 0.90% 0.89% 0.94% 1.05% 0.98%
9.53% 8.70% 8.21% 8.15% 9.65% 10.00% 10.46% 11.26% 11.57% 11.65% 11.63% 11.32%
38.04% 38.67% 39.31% 39.21% 37.80% 18.95% 18.47% 17.63% 17.32% 17.17% 17.11% 17.47%
No. of Shareholders 32,66629,57330,61829,41826,64221,58420,87721,17120,62120,37421,47221,621

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls